Pharsight

Mektovi patents expiration

MEKTOVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(1 year, 2 months ago)

US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(9 months from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(1 year, 2 months ago)

US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(1 year, 2 months ago)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(6 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(7 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(9 years from now)

Mektovi is owned by Array Biopharma Inc.

Mektovi contains Binimetinib.

Mektovi has a total of 11 drug patents out of which 3 drug patents have expired.

Expired drug patents of Mektovi are:

  • US8193229
  • US8513293
  • US8178693

Mektovi was authorised for market use on 27 June, 2018.

Mektovi is available in tablet;oral dosage forms.

Mektovi can be used as indicated in combination with encorafenib for the treatment of melanoma, mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-approved test, indicated in combination with encorafenib for the treatment of melanoma with a braf mutation, method of treating melanoma, treatment of melanoma with a braf mutation.

Drug patent challenges can be filed against Mektovi from 27 June, 2022.

The generics of Mektovi are possible to be released after 18 October, 2033.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-194) Jun 27, 2025
New Indication(I-928) Oct 11, 2026
New Chemical Entity Exclusivity(NCE) Jun 27, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: 27 June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Mekt...

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage

MEKTOVI family patents

Family Patents